One of the most intriguing areas in today’s pharmaceutical sector is the topic of orphan drugs. Orphan drugs are drugs that are used to treat rare diseases – for example, Orkambi and Kalydeco, two drugs brought to market by Vertex…continue reading →
One of the simplest techniques to help determine investment merit was actually made by a co-worker of mine. A couple of colleagues and I were discussing investment styles and strategies that had served them well over the years. One was…continue reading →
As a publication dedicated to helping people meet investment goals through educated decision-making, In Sickness and Wealth is pleased to share this must-read article! I have had the honor and pleasure of knowing Diane Garnick for nearly 20 years now.…continue reading →
On December 13th, Obama signed into law the 21st Century Cures Act. It enacts significant investments for innovative technologies and research to positively impact patients… undoubtedly through some of the healthcare companies in our portfolio and the many others we…continue reading →
With less than two weeks to go in 2016, there are some clear-cut winners in healthcare and some pretty dismal performances as well. The two benchmarks we watch carefully are the S&P 500 and the S&P 500 Healthcare sector as…continue reading →
Sometimes we fail to deliver better healthcare, not because a treatment doesn’t exist or science can’t develop one, but because it can’t survive the logistics of access, delivery, and sustainability. Good business is investing in activities that can achieve both... In Sickness and Wealth... as we explore innovative companies and how they deliver value.
David Lerman / Jodie Warner - Editors